Drug Information

Drug General Information
Drug ID
D0N9GI
Former ID
DNC000526
Drug Name
DDAVP
Drug Type
Small molecular drug
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Approved [522431]
Structure
Download
2D MOL

3D MOL
Formula
C46H64N14O12S2
Canonical SMILES
C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C<br />(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(<br />=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N
InChI
1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)
InChIKey
NFLWUMRGJYTJIN-UHFFFAOYSA-N
CAS Number
CAS 302-40-9
PubChem Compound ID
27991
PubChem Substance ID
9159, 7783794, 7847357, 34670467, 50064536, 50070798, 53787253, 57310566, 77063836, 85209724, 103227081, 104301501, 117569670, 125433002, 131301306, 134337402, 134339931, 135652083, 135652102, 136351194, 138069845, 141754311, 144224269, 163621049, 163686372, 198993895, 238569930, 247860472
Target and Pathway
Target(s) Vasopressin V2 receptor Target Info Agonist [535006], [536397], [537856], [537914]
KEGG Pathway Neuroactive ligand-receptor interaction
Vasopressin-regulated water reabsorption
Pathway Interaction Database Arf6 trafficking events
PathWhiz Pathway Vasopressin Regulation of Water Homeostasis
Reactome Vasopressin-like receptors
G alpha (s) signalling events
Vasopressin regulates renal water homeostasis via Aquaporins
WikiPathways GPCRs, Class A Rhodopsin-like
Regulation of Water Balance by Renal Aquaporins
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 522431ClinicalTrials.gov (NCT00748072) 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy. U.S. National Institutes of Health.
Ref 535006Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000 Jul;106(1):107-16.
Ref 536397Hydronephrosis: prevention by restoration of urinary concentrating ability using desamino-8D-arginine vasopressin (DDAVP) in Brattleboro rats. Int J Exp Pathol. 1991 Oct;72(5):581-7.
Ref 537856An extracellular residue determines the agonist specificity of V2 vasopressin receptors. FEBS Lett. 1995 Mar 27;362(1):19-23.
Ref 537914The abnormal quinine drinking aversion in the Brattleboro rat with diabetes insipidus is reversed by the vasopressin agonist DDAVP: a possible role for vasopressin in the motivation to drink. PhysiolBehav. 1994 Mar;55(3):407-12.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.